| Description | Miglustat hydrochloride (N-Butyldeoxynojirimycin hydrochloride) is an inhibitor of glucosylceramide synthase and can be used for studies about Type I Gaucher disease. |
| In vivo | 在标准高脂早餐摄入30分钟内服用 Miglustat hydrochloride 会显著降低峰值暴露量，但对 Miglustat hydrochloride 的全身暴露程度没有显著影响。食物共同给药后，Cmax 平均降低了36%。食物共同给药时，AUC 轻微下降了14%，但90%置信区间仍在80%至125%的接受范围内。在禁食状态下，Tmax 为2.5（1.0-4.0）小时，而在进食状态下延长至4.5（1.5-8.0）小时，然而表观终末半衰期大约为8小时，且不受食物影响[1]。 |
| Synonyms | NB-DNJ hydrochloride, 盐酸美格鲁特, N-Butyldeoxynojirimycin hydrochloride, OGT918 hydrochloride |
| molecular weight | 255.74 |
| Molecular formula | C10H22ClNO4 |
| CAS | 210110-90-0 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | H2O: 34 mg/mL (132.95 mM) DMSO: 60 mg/mL (234.61 mM), Sonication is recommended. |
| References | 1. van Giersbergen, P.L. and J. Dingemanse, Influence of food intake on the pharmacokinetics of miglustat, an inhibitor of glucosylceramide synthase. J Clin Pharmacol, 2007. 47(10): p. 1277-82. 2. Abian, O., et al., Therapeutic strategies for Gaucher disease: miglustat (NB-DNJ) as a pharmacological chaperone for glucocerebrosidase and the different thermostability of velaglucerase alfa and imiglucerase. Mol Pharm, 2011. 8(6): p. 2390-7. |